These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27930669)

  • 21. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
    Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
    Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
    Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
    BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked.
    Nassar AH; Lundgren K; Pomerantz M; Van Allen E; Harshman L; Choudhury AD; Preston MA; Steele GS; Mouw KW; Wei XX; McGregor BA; Choueiri TK; Bellmunt J; Kwiatkowski DJ; Sonpavde GP
    JCO Precis Oncol; 2018; 2():. PubMed ID: 33604498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
    Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
    Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGFR3-TACC3 fusion in solid tumors: mini review.
    Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
    Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
    Shibata N; Cho N; Koyama H; Naito M
    Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).
    Roperch JP; Hennion C
    BMC Med Genet; 2020 May; 21(1):112. PubMed ID: 32448160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
    Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue.
    Fritsch MK; Bridge JA; Schuster AE; Perlman EJ; Argani P
    Pediatr Dev Pathol; 2003; 6(1):43-53. PubMed ID: 12375129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
    McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
    Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay.
    Lanic MD; Le Loarer F; Rainville V; Sater V; Viennot M; Beaussire L; Viailly PJ; Angot E; Hostein I; Jardin F; Ruminy P; Laé M
    Mod Pathol; 2022 May; 35(5):649-663. PubMed ID: 35075283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.
    Toussaint J; Sieuwerts AM; Haibe-Kains B; Desmedt C; Rouas G; Harris AL; Larsimont D; Piccart M; Foekens JA; Durbecq V; Sotiriou C
    BMC Genomics; 2009 Sep; 10():424. PubMed ID: 19744330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR3 signaling and function in triple negative breast cancer.
    Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
    Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
    Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
    Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
    Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.